Plozasiran for Severe Hypertriglyceridemia

Name: Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC
Uploaded: 2026-09-02T04:00:00+00:00
Duration: 3 min 15 s
Description: From ESC 2026 in Munich, Dr. Gerald Watts explores the 12-month findings from the phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in patients with sever

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
Heart Matters
Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
Charles Turck, PharmD, BCPS, BCCCP; Akshay Kumar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Akshay Kumar, MD
A More Complete View of Cardiovascular Risk in Women
A More Complete View of Cardiovascular Risk in Women
Heart Matters
A More Complete View of Cardiovascular Risk in Women
Noel Bairey Merz, MD
- Noel Bairey Merz, MD
Updated AACE Guidance on Managing Dyslipidemia in T2D
Updated AACE Guidance on Managing Dyslipidemia in T2D
Heart Matters
Updated AACE Guidance on Managing Dyslipidemia in T2D
Scott D. Isaacs, MD FACP, FACE
- Scott D. Isaacs, MD FACP, FACE
Applying Guideline Recommendations to ACS Management
Applying Guideline Recommendations to ACS Management
Heart Matters
Applying Guideline Recommendations to ACS Management
Steve Jackson, PharmD; Sunil Rao, MD
- Steve Jackson, PharmD
- Sunil Rao, MD

Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC

Recommended

Title

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy